R. Orlando, P. Piccoli, Sara De Martin
Jan 1, 2004
Citations
1
Influential Citations
105
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
This study was designed (1) to evaluate the effect of a cytochrome P450 (CYP) 1A2 inhibitor, fluvoxamine, on the pharmacokinetics of intravenous lidocaine and its 2 pharmacologically active metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX), to confirm recent in vitro results indicating that CYP1A2 is the main isoform responsible for lidocaine biotransformation and (2) to assess whether liver function has any influence on the fluvoxamine‐lidocaine interaction.